Results 111 to 120 of about 52,054 (406)
LIVER TRANSPLANTATION FOR TYPE I GLYCOGEN STORAGE DISEASE [PDF]
A 16½-year-old girl with type I glycogen storage disease was treated by orthotopic liver transplantation under cyclosporin/steroid immunosuppression. All metabolic stigmata of the disease were relieved and 1 year postoperatively she follows a normal diet
Alper +15 more
core +1 more source
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley +1 more source
Substrate reduction therapy for inborn errors of metabolism
Inborn errors of metabolism (IEM) represent a growing group of monogenic disorders each associated with inherited defects in a metabolic enzyme or regulatory protein, leading to biochemical abnormalities arising from a metabolic block.
W. Yue, S. Mackinnon, G. A. Bezerra
semanticscholar +1 more source
The ClinGen Inborn Errors of Metabolism Working Group was tasked with creating a comprehensive, standardized knowledge base of genes and variants for metabolic diseases.
Diane B. Zastrow +22 more
semanticscholar +1 more source
Is susceptibility to severe
Peter T. Clayton
openalex +1 more source
Amino Acids and Acylcarnitines Reference Values for Neonatal Screening of Inborn Errors of Metabolism in Colombia by Tandem Mass Spectrometry [PDF]
Antonio Bermúdez +3 more
openalex +1 more source
Pharmacokinetics of teicoplanin in paediatric patients—A systematic review of current literature
Background and Objective Teicoplanin is commonly used in children to treat gram‐positive infections and is sometimes used off‐label prophylactically in surgical or paediatric oncology settings. The pharmacokinetics (PK) of teicoplanin in children exhibit considerable variability, such as in critically ill children or those with renal impairment.
Noa E. Wijnen +4 more
wiley +1 more source
Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang +5 more
wiley +1 more source
Metabolomics: a challenge for detecting and monitoring inborn errors of metabolism.
Timely newborn screening and genetic profiling are crucial in early recognition and treatment of inborn errors of metabolism (IEMs). A proposed nosology of IEMs has inserted 1,015 well-characterized IEMs causing alterations in specific metabolic pathways.
M. Mussap, M. Zaffanello, V. Fanos
semanticscholar +1 more source
Screening for inborn errors of metabolism using untargeted metabolomics and out-of-batch controls [PDF]
Michiel Bongaerts +10 more
openalex +1 more source

